Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients

Ollivier-Hourmand, Isabelle; Lebedel, Louise; Lecouf, Angélique Thuillier; Allaire, Manon; Nguyen, Toan T.; Lier, Christina J. van; Dao, Thông

doi:10.1186/s12879-020-05212-2

Cited by 5 publications

(1 citation statement)

References 21 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Close monitoring is needed if it is used in transplant recipients because of an increased risk of acute humoral and cellular rejection[ 179 , 180 ]. Peg-IFN was thought to be safe only in liver transplant recipients until recent case reports described its successful use in a kidney transplant recipient[ 181 - 183 ].…”

Section: Treatmentmentioning

confidence: 99%

Transfusion-transmitted hepatitis E: What we know so far?

Cheung¹,

Wong²,

Law³

et al. 2022

WJG

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is a major cause of viral hepatitis globally. There is growing concern about transfusion-transmitted HEV (TT-HEV) as an emerging global health problem. HEV can potentially result in chronic infection in immunocompromised patients, leading to a higher risk of liver cirrhosis and even death. Between 0.0013% and 0.281% of asymptomatic blood donors around the world have HEV viremia, and 0.27% to 60.5% have anti-HEV immunoglobulin G. HEV is infectious even at very low blood concentrations of the virus. Immunosuppressed patients who develop persistent hepatitis E infection should have their immunosuppressant regimen reduced; ribavirin may be considered as treatment. Pegylated interferon can be considered in those who are refractory or intolerant to ribavirin. Sofosbuvir, a nucleotide analog, showed modest antiviral activity in some clinical studies but sustained viral response was not achieved. Therefore, rescue treatment remains an unmet need. The need for HEV screening of all blood donations remains controversial. Universal screening has been adopted in some countries after consideration of risk and resource availability. Various pathogen reduction methods have also been proposed to reduce the risk of TT-HEV. Future studies are needed to define the incidence of transmission through transfusion, their clinical features, outcomes and prognosis.

show abstract